Skip to main content
KBS_Icon_questionmark link-ico

Baseline Biomarker Check (BBC) Study

Predicting treatment response in people experiencing a first episode of psychosis: using biological markers to improve drug selection and treatment.

King’s College London are launching a new clinical study called the Baseline Biomarker Check study. This website describes the aims of the study, who we wish to take part, and what the study involves. This information should help you to understand whether you may be interested in or eligible to take part in the BBC study

About the study

The aim of the Baseline Biomarker Check (BBC) study is to explore whether biological markers (so called ‘biomarkers’) can help us to predict how well a patient with psychosis may respond to a medication.

We plan to develop a tool to predict treatment outcome for people experiencing their first episode of psychosis.

The study is a collaboration between the Department of Psychosis Studies in the Institute of Psychiatry, Psychology & Neuroscience at King's College London and the South London and Maudsley NHS Foundation Trust.

We are currently looking to recruit patients experiencing a first episode of psychosis as well as individuals who have never experienced psychosis.


Contact us

If you are interested in participating, or are working with a service user who is, please get in touch with the Department of Psychosis Studies:

020 7123 4587

Institute of Psychiatry, Psychology & Neuroscience (IoPPN), IoPPN, 16 De Crespigny Park, London SE5 8AB


Psychosis is a medical disorder that affects how the brain processes information and can cause symptoms such as hallucinations (where a person experiences things, such as voices, which are not really there). Psychotic symptoms can be very distressing for those who suffer from them and their friends and families.

Patients suffering psychosis are often offered medication, called antipsychotics, to help with their symptoms. Some patients do not respond well to antipsychotic medication and so do not make a good recovery. At present, we are unable to reliably predict who will respond well to antipsychotic medication. This information would allow clinicians to be able to plan care around each service-users' needs better.



What will happen during the visit?

What are the benefits of taking part?

You will be reimbursed for your time.

By participating, you will contribute to the development of medical knowledge.

If you are a patient, as part of the study, some of the information we collect may be helpful for doctors involved in planning your care.

Our partners